Public Employees Retirement Association of Colorado Sells 2,974 Shares of DexCom, Inc. (NASDAQ:DXCM)

Public Employees Retirement Association of Colorado reduced its stake in DexCom, Inc. (NASDAQ:DXCM) by 5.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 55,298 shares of the medical device company’s stock after selling 2,974 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in DexCom were worth $7,670,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. DSM Capital Partners LLC bought a new position in shares of DexCom in the fourth quarter worth about $28,000. Crewe Advisors LLC bought a new stake in DexCom during the 1st quarter worth approximately $29,000. Valley National Advisers Inc. lifted its holdings in DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. Riverview Trust Co bought a new position in shares of DexCom in the first quarter worth approximately $32,000. Finally, MV Capital Management Inc. increased its stake in shares of DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after purchasing an additional 138 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Trading Up 5.4 %

Shares of NASDAQ DXCM opened at $67.48 on Tuesday. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. The business’s 50 day moving average is $114.02 and its two-hundred day moving average is $123.33. The stock has a market capitalization of $27.04 billion, a P/E ratio of 43.54, a PEG ratio of 1.58 and a beta of 1.16.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.04. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the previous year, the company posted $0.34 EPS. The company’s revenue for the quarter was up 15.3% compared to the same quarter last year. As a group, research analysts expect that DexCom, Inc. will post 1.76 EPS for the current year.

Insider Buying and Selling at DexCom

In other news, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $119.24, for a total value of $77,744.48. Following the completion of the sale, the executive vice president now owns 67,560 shares in the company, valued at approximately $8,055,854.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Sadie Stern sold 427 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $49,126.35. Following the transaction, the executive vice president now owns 75,877 shares of the company’s stock, valued at $8,729,648.85. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $119.24, for a total value of $77,744.48. Following the sale, the executive vice president now directly owns 67,560 shares of the company’s stock, valued at $8,055,854.40. The disclosure for this sale can be found here. Insiders have sold 3,483 shares of company stock worth $401,450 over the last quarter. Insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

DXCM has been the subject of several recent analyst reports. Wells Fargo & Company dropped their target price on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating for the company in a report on Friday. Royal Bank of Canada lowered their price objective on DexCom from $165.00 to $145.00 and set an “outperform” rating on the stock in a research report on Friday. Citigroup increased their target price on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Stifel Nicolaus dropped their price target on DexCom from $132.00 to $90.00 and set a “buy” rating for the company in a research note on Friday. Finally, BTIG Research cut their price objective on shares of DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a report on Friday. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $111.50.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.